Listed by the USPTO as CORNELIUS, CLAIRE ADRIENNE
Tech Center 1600 • Art Units: 1600 1618 1632 1671 1672
This examiner grants 71% of resolved cases
CORNELIUS, CLAIRE ADRIENNE is assigned to Tech Center 1600 and Art Unit 1600. The profile includes 7 resolved cases, a 71.4% allowance rate, and a 1056-day median to allowance. The interview lift is 0.0%, so the available data does not show an interview-associated change in allowance outcomes.
The listed companies are CJ CheilJedang Corporation, Zoetis LLC, and Dyno Therapeutics Inc. The listed firms are Morgan, Lewis & Bockius LLP (WA), Adler Pollock & Sheehan P.C., and Biospark Intellectual Property Law. Because the case volume is limited, practitioners should rely on application-specific prosecution analysis rather than broad examiner inferences.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18277873 | NOVEL BACTERIOPHAGE HAVING CLOSTRIDIUM PERFRINGENS-SPECIFIC BACTERICIDAL EFFECT AND ANTIBACTERIAL COMPOSITION COMPRISING SAME | Final Rejection | CJ CheilJedang Corporation |
| 18278878 | NOVEL BACTERIOPHAGE HAVING CLOSTRIDIUM PERFRINGENS-SPECIFIC BACTERICIDAL EFFECT AND ANTIBACTERIAL COMPOSITION COMPRISING SAME | Final Rejection | CJ CHEILJEDANG CORPORATION |
| 18721713 | COMPOSITIONS AND METHODS FOR EXPRESSING ANTIGENS ON CELL MEMBRANE | Non-Final OA | Zoetis Services LLC |
| 18511416 | Virus-like Particles with Programmable Tropism and Methods of Use Thereof for Delivery to Cells | Non-Final OA | The General Hospital Corporation |
| 18727308 | CIRCULAR RNA VACCINES AGAINST SARS-COV-2 VARIANTS AND METHODS OF USE THEREOF | Non-Final OA | Peking University |
| 19000508 | ANTIBODIES FOR TREATMENT OF CORONAVIRUS DISEASE | Non-Final OA | The Texas A&M University System |
| 18277425 | NOVEL DRUGGABLE REGIONS IN THE HUMAN CYTOMEGALOVIRUS GLYCOPROTEIN B POLYPEPTIDE AND METHODS OF USE THEREOF | Non-Final OA | Pfizer Inc. |
| 18301542 | TREATMENT OF INFLAMMATORY CONDITIONS | Non-Final OA | Kyoto University |
| 18350357 | FOAM VACCINATION OF AVIANS | Non-Final OA | UNIVERSITY OF DELAWARE |
| 18262073 | Therapeutic Viral Vaccine | Final Rejection | GlaxoSmithKline Biologicals SA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy71.4% of resolved applications examined by Claire Adrienne Cornelius were allowed (7 resolved cases), compared with 37.3% across Art Unit 1600 over the last five years.
This examiner's interview lift is +0.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Claire Adrienne Cornelius took 1,056 days on average from filing to allowance.
Claire Adrienne Cornelius examines applications in Art Unit 1600 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
